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Abstract. 
 
Calpains and caspases are two cysteine pro-
tease families that play important roles in regulating 
pathological cell death. Here, we report that m-calpain 
may be responsible for cleaving procaspase-12, a 
caspase localized in the ER, to generate active caspase-
12. In addition, calpain may be responsible for cleaving 
the loop region in Bcl-xL and, therefore, turning an an-
tiapoptotic molecule into a proapoptotic molecule. We 
propose that disturbance to intracellular calcium stor-
 
age as a result of ischemic injury or amyloid 
 
b
 
 peptide 
cytotoxicity may induce apoptosis through calpain-
mediated caspase-12 activation and Bcl-xL inactivation. 
These data suggest a novel apoptotic pathway involving 
calcium-mediated calpain activation and cross-talks be-
tween calpain and caspase families.
Key words: calcium • Alzheimer’s disease • Bcl-xL • 
endoplasmic reticulum • ER stress
 
Introduction
 
Calpains and caspases are two families of cysteine pro-
teases that may be involved in mediating both acute and
chronic neuronal cell deaths (Chan and Mattson, 1999).
Calpains are cytosolic calcium-activated neutral cysteine
endopeptidases, and are ubiquitously distributed in all ani-
mal cells (Croall and Demartino, 1991; Saido et al., 1994).
The calpain family has at least six members, which can be
divided into two groups based upon their tissue distribu-
tion: ubiquitous and tissue specific. The best characterized
calpains are two ubiquitously expressed isozymes, 
 
m
 
- and
m-calpain, which can be distinguished by their in vitro re-
quirement for different levels of calcium for activation.
 
m
 
-Calpain is activated in the presence of micromolar con-
centrations of calcium, whereas m-calpain requires milli-
molar concentrations of calcium (Croall and Demartino,
1991; Saido et al., 1994). Calpain-mediated proteolysis
proceeds in a limited manner but does not require a spe-
cific amino acid residue like that of caspases. Calpain has
been proposed to play a role in regulating normal signal
transduction processes by cleaving cytoskeletal proteins
such as talin and 
 
a
 
-actinin; membrane proteins such as the
EGF receptor, integrin, N-CAM, and cadherin; and en-
zymes such as protein kinase C and calmodulin-dependent
kinase (Saido et al., 1994). Calpain may play an important
role in pathogenesis of diseases. Calpain activation has
been proposed to contribute to neuronal cell death in isch-
emic brain injury (Saido et al., 1994), Alzheimer’s disease
(Saito et al., 1993; Tsuji et al., 1998), and myelin protein
degradation in multiple sclerosis (Shields et al., 1998).
Calpain inhibitors have been shown to have neuroprotec-
tive effects in models of focal (Markgraf et al., 1998) or
global (Li et al., 1998) cerebral ischemia, delayed neuronal
death after transient ischemia (Yokota et al., 1999), and
myocardial infarction (Toda et al., 1989).
Caspases are mammalian homologues of 
 
Caenorhabditis
elegans
 
 cell death gene product Ced-3, and they play an
important role in regulating apoptosis (Zheng et al., 1999).
14 members of the mammalian caspase family have been
identified that are widely expressed in a variety of tissues
and cell types. Like calpain, caspases normally exist in
cells as proenzymes, which may be activated through re-
cruitment into activating complexes or direct proteolytic
cleavage by another caspase (Cryns and Yuan, 1998).
Caspase activation has been shown to contribute to cell
death in the ischemic brain (Namura et al., 1998), isch-
emic heart injury (Bialik et al., 1999) and neuronal loss in
chronic neurodegenerative diseases such as Alzheimer’s
disease (Gervais et al., 1999) and Huntington’s disease–
related polyglutamine repeat expansion diseases (Sanchez
et al., 1999; Sawa et al., 1999). Although calpain and cas-
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pase have both been proposed to play important roles in
regulating pathological neuronal cell death, the interac-
tions of these two families of proteases under pathological
conditions are not clear.
In contrast to calpains, which mainly exist in the cytosol
when inactive, procaspases may be present in different
subcellular locations. For example, caspase-1 and caspase-3
are predominantly cytosolic (Nakagawa et al., 2000) while
at least a portion of caspase-9 is mitochondrial (Li et al.,
1997). Recently, we demonstrated a novel ER-specific ap-
optosis pathway mediated by caspase-12 (Nakagawa et al.,
2000). We showed that procaspase-12 is predominantly lo-
calized at the ER, and is specifically activated by distur-
bances to ER homeostasis such as ER stress and mobiliza-
tion of intracellular calcium ion store (Nakagawa et al.,
2000). Caspase-12
 
2
 
/
 
2
 
 mice are resistant to tunicamycin-
induced renal epithelial cell death and lethality. Caspase-
12
 
2
 
/
 
2
 
 cortical neurons are resistant to amyloid-
 
b
 
 protein–
mediated neurotoxicity (Nakagawa et al., 2000). Since
caspase-12 may play a critical role in regulating pathologi-
cal cell death, it is important to understand its mechanism
of activation.
ER plays a central role in protein biosynthesis and is
also the major intracellular organelle involved in calcium
storage. Intracellular calcium concentration is regulated
by a combination of actions of calcium channels, calcium-
binding proteins, and sequestration to the ER and other
intracellular spaces. The calcium ion is involved in regulat-
ing many physiological events, such as fertilization, prolif-
eration, and learning and memory in the central nervous
system (Berridge, 1993). Physiological release of calcium
from ER storage is mediated through binding of inositol
1,4,5-triphosphate to inositol 1,4,5-trisphosphate receptor
(IP3R)
 
1
 
 at the ER (Furuichi et al., 1989). Disruption of in-
tracellular calcium homeostasis can often be lethal to cells
(Berridge et al., 1998). Inhibition of N-glycosylation by tu-
nicamycin and alterations of intracellular calcium homeo-
stasis result in accumulation of unfolded proteins in ER
and lead to induction of chaperone proteins and elevation
of intracellular calcium, a phenomenon termed unfolded
protein response or ER stress (Buckley and Whorton,
1997; Sidrauski et al., 1998). Treatment of thapsigargin, an
inhibitor of the intracellular calcium-ATP transporter and
calcium ionophore (A23187), induces the elevation of cal-
cium concentration in the cytosol. Disruption of intracellu-
lar calcium homeostasis also has been shown to contribute
to neuronal degenerative diseases. Mutations in preseni-
lin-1, a protein predominantly localized in ER, have been
linked to the majority of inherited early onset Alzheimer’s
disease (Alzheimer’s Disease Collaborative Group, 1995).
Expression of mutant presenilin-1 disturbs the intracellu-
lar calcium homeostasis (Leissring et al., 1999). Synapto-
somes from transgenic mice harboring presenilin-1 muta-
tions exhibit elevated cytoplasmic calcium (Begley et al.,
1999). These data suggest that the disturbance in the intra-
cellular calcium homeostasis may contribute to the patho-
genesis of Alzheimer’s disease involving expression of mu-
tant presenilin-1. Recently, calpain has been shown to
 
cleave p35 to generate a toxic p25 fragment under neuro-
toxic conditions including ischemia and amyloid-
 
b
 
 treat-
ment (Patrick et al., 1999; Lee et al., 2000). These data
indicated that disturbance in calcium homeostasis and
calpain activation may contribute to ischemic neuronal in-
jury and amyloid-
 
b
 
 cytotoxicity.
Since both calpain and caspase-12 are activated by ele-
vated intracellular calcium and both may play important
roles in mediating neuronal degeneration, we examined
the possible interaction between these two cysteine pro-
teases. We demonstrate here that calpain is required for
caspase-12 activation. Furthermore, we show that isch-
emia-induced calpain activation results in the Bcl-xL
cleavage and most likely transformation of this antiapop-
totic molecule into a proapoptotic form. We propose a
novel pathway of calpain-mediated caspase-12 activation
induced by disturbance of intracellular calcium homeo-
stasis.
 
Materials and Methods
 
Materials
 
We used the following antibodies for Western blotting and chemicals for
cell culture. Bcl-xL/S polyclonal antibody and Bcl-2 monoclonal antibody
were purchased from Santa Cruz Biotechnology, Inc. Tubulin antibody
was purchased from Sigma Chemical Co. IP3R antibody was purchased
from Calbiochem. Grp78 and 94, calreticulin antibodies were purchased
from Stressgen. 
 
a
 
-Spectrin antibody was a gift from M.S. Lee and L.H.
Tsai (Harvard Medical School, Boston, MA). Calpain inhibitor I (
 
N
 
-
acetyl-Leu-Leu-Nle-CHO), II (
 
N
 
-acetyl-Leu-Leu-Met-CHO), and E-64d
were purchased from Sigma Chemical Co. E-64 was purchased from
Boehringer Mannheim. MDL28170 was a gift from Hoechst Marion Rous-
sel, zVAD and amyloid 
 
b
 
 were purchased from Bachem.
 
Limited Digestion of Microsomal Proteins
 
Kidney microsome was prepared as described previously (Nakagawa et
al., 2000). Microsomal proteins were digested by 0.05% trypsin-EDTA
(GIBCO BRL) or HBSS (
 
2
 
) at 37
 
8
 
C for 5 or 10 min, and the reaction was
stopped by adding SDS sample buffer. Proteins were analyzed by Western
blotting using anti–caspase-12, anti-IP3R, anti-grp78 (BiP) and grp94, and
anticalreticulin antibodies.
 
Cell Culture and Induction of Cell Death
 
Mixed glial cells were prepared from C57BL/6J mice around embryonic
day 18. In brief, mouse brain cortex, free of meninges, was dissected and
passed through a mesh (200–300 
 
m
 
m). Cells were collected by centrifuga-
tion (160 
 
g
 
, 5 min) and resuspended in culture medium containing MEM
with 10% FBS, 5 mg/ml insulin, and 2% glucose. Cells were washed three
times with DME without glucose (oxygen and glucose deprivation
[OGD]), or with complete medium (oxygen deprivation [OD]), and then
transferred to anaerobic chamber for hypoxia.
Primary cortical neurons were prepared as described previously (Naka-
gawa et al., 2000). 5 
 
3 
 
10
 
5
 
/ml of cortical neurons were suspended in me-
dium containing B27 in DME/F-12, and 4 d later 40 
 
m
 
M fibrillar A
 
b
 
 (25-
35) or 40 
 
m
 
M of fibrillar A
 
b
 
 (25-35) plus 28 
 
m
 
M E-64 or 10 
 
m
 
M MDL28170
were added to cells. Calpain inhibitors were added every 24 h. Cells were
collected after 48-h treatment.
2 
 
3
 
 10
 
5
 
/ml of Rat1 cells were suspended in medium containing 10%
FBS in DME. Full-length (1.6 
 
m
 
g) or truncated caspase-12 (1.6 
 
m
 
g) or
pcDNA3 vector (1.6 
 
m
 
g) was transfected into Rat1 cells by the calcium
phosphate method. The percentages of cell death were determined by
morphology 24 h after transfection.
 
Cerebral Cortical S-100 and Cleavage Assay
 
Cortical S-100 was prepared in buffer B (20 mM Tris-HCl, pH 7.6, 2 mM
EDTA, 10 mM EGTA, 0.25 M sucrose). A total of 300 
 
m
 
g
 
 
 
S-100 was used
for the cleavage assay in buffer C (12 mM Tris-HCl, pH 8.0, 5 mM 
 
b
 
-mer-
 
1
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b
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cose deprivation; t-caspase-12, T159-N419 caspase-12. 
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captoethanol, 0.2 mM EDTA, 1 mM EGTA, 25 mM sucrose plus calcium)
at 30
 
8
 
C. 2 mM EDTA and 5 mM EGTA were added for calcium chelating.
 
In Vitro Cleavage Reaction by m-Calpain
 
pcDNA3.1 (Invitrogen)-Bcl-xL and pcDNA3/caspase-12 were tran-
scribed and translated in vitro using a TNT kit (Promega) in the pres-
ence of [
 
35
 
S]methionine. In vitro cleavage reactions were performed in a
buffer containing 150 mM NaCl, 20 mM Tris-Cl, pH 7.6, 1 mM DTT, and
100 mg/ml BSA with 5 mM calcium and m-calpain (1 U/ml; Sigma
Chemical Co.) at 25
 
8
 
C. Reactions were terminated by the addition of
SDS buffer and boiling. Samples were analyzed by SDS-PAGE and
autoradiography.
 
Amino Acid Sequencing
 
pRSET (Invitrogen)-truncated mutant caspase-12 or pGEX-6P (Pharma-
cia Biotech) full-length Bcl-xL fusion proteins were cleaved in vitro by
m-calpain (2 U) for 15 min at room temperature. Cleaved products were
transferred to PVDF membrane (BioRad) and NH
 
2
 
-terminal peptides
were sequenced by PE/ABD Procise 494 HT protein sequencing system
(Harvard MicroChem).
 
Active Caspase-12 Bacteria Lysate and In
Vitro Reaction
 
Escherichia coli
 
 HMS (DE3) pLysS carrying either pGEX-2T (Pharmacia
Biotech) or expression plasmids, pRSET-truncated (T159-N419) caspase-
12, was cultured in LB medium at 18
 
8
 
C for 12 h with 0.4 mM isopropyl-
 
b
 
-
 
D
 
-thiogalactopyranoside for induction of the recombinant protein. 
 
E.
coli 
 
was harvested, washed in PBS, and broken by lysozyme and sonica-
tion in 25 mM Hepes, pH 7.5, 10% sucrose, 0.1% CHAPS, and 0.1 mM
PMSF. The supernatant was used as active lysates after centrifugation at
16,000 
 
g
 
 for 30 min. 
 
35
 
S-truncated caspase-12 was incubated with bacterial
lysates in cleavage buffer (100 mM Hepes, pH 7.5, 10% sucrose, 0.1%
CHAPS, 10 mM DTT, and 0.1 mM PMSF) at 37
 
8
 
C for 3 h, and analyzed
by SDS-PAGE and autoradiography.
 
Results
 
Expression Pattern of Mouse Caspase-12
 
To determine the tissue expression pattern of caspase-12,
we stained Western blots of mouse tissue lysates using an
anti–caspase-12 antibody. We found that caspase-12 is
ubiquitously expressed in postnatal day 4 mouse tissues
(Fig. 1 A). Caspase-1 is also ubiquitously expressed, but
the expression levels of caspase-1 are different from that
of caspase-12 (Fig. 1 A). Caspase-12 expression was de-
tected in the lysates of purified cortical neurons and glial
cells (data not shown). We concluded that caspase-12 is
widely expressed in a variety of cells.
 
Caspase-12 Is Localized on the Cytoplasmic Side of
the ER
 
We have shown that procaspase-12 is localized in the ER
(Nakagawa et al., 2000). To understand the mechanism of
caspase-12 activation, we determined whether caspase-12
is localized on the lumenal or cytoplasmic side of the ER.
We prepared the mouse kidney microsomal fraction and
analyzed the orientation of caspase-12 by limited trypsin
digestion (Fig. 1 B). We found that caspase-12, like the IP3
receptor, an ER resident protein facing the cytoplasmic
side (Furuichi et al., 1989) was quickly digested by trypsin
treatment (Fig. 1 B). In contrast, grp78 (BiP), grp94, and
calreticulin, which are localized on the lumenal side of
ER, were protected from trypsin digestion. These data in-
dicate that caspase-12 is localized on the cytoplasmic side
of the ER.
 
Cleavage of Caspase-12 and Bcl-xL after Oxygen and 
Glucose Deprivation
 
To determine the mechanism of caspase-12 activation, we
examined caspase-12 processing in apoptotic glial cells.
We have previously shown that caspase-12 is specifically
activated by apoptotic stimuli with an ER stress compo-
nent (Nakagawa et al., 2000). We found that oxygen and
glucose deprivation (OGD) in cultured glial cells, which
mimics ischemic condition in vivo, induced an ER stress
response efficiently, as indicated by the induction of grp78
(BiP) and grp 94 using Western blot analysis (Fig. 2 A).
Caspase-12 was cleaved into a number of protein frag-
ments 
 
z
 
35 kD in glial cells after treatment of OGD (Fig. 2
A), thapsigargin (2
 
 m
 
M), or A23187 (2 
 
m
 
M; Fig. 2 B). Con-
sistent with the requirement of ER stress response for
caspase-12 activation (Nakagawa et al. 2000), hypoxia
(OD) alone did not induce BiP expression nor did it in-
duce caspase-12 cleavage (Fig. 2 A). Interestingly, Bcl-xL,
but not Bcl-2, was cleaved into a 25-kD proteolytic frag-
ment in oxygen- and glucose-deprived glial cells (Fig. 2 A).
We ruled out the possibility that this 25-kD protein was
Bcl-xS, an alternative spliced form of Bcl-xL (Boise et
al., 1993). Although Bcl-xL mRNA was detected, Bcl-xS
mRNA was not detected in glial cells after OGD treat-
ment by reverse transcriptase–PCR (data not shown).
Since an antibody generated against the COOH-terminal
end of Bcl-xL detects this 25-kD protein, the cleavage site
is most likely in the loop domain of Bcl-xL (see below).
 
Inhibition of Caspase-12 and Bcl-xL Cleavage by 
Calpain Inhibitors
 
Since ER stress agents, tunicamycin, thapsigargin, and
A23187, are all capable of inducing increases in cytosolic
calcium concentration and calpain has been shown to play
a role in mediating ischemic brain injury (Saido et al.,
Figure 1. The expression of caspase-12. (A) A Western blot of
caspase-12. Anti–caspase-1 and antitubulin antibodies were used
as controls. Caspase-12 is constitutively expressed in postnatal
day 4 mouse tissues. (B) Caspase-12 localizes on the outer mem-
brane of the ER. IP3R, a transmembrane protein, was readily di-
gested by trypsin as that of caspase-12, whereas ER lumenal pro-
teins, grp78, grp94, and calreticulin were protected against
trypsin digestion. ut, untreated. 
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1994) and kidney necrosis (Edelstein et al., 1995), we ex-
amined the possible involvement of calpain in caspase-12
activation (Fig. 2, C and D). Glial cells were subjected to
oxygen and glucose deprivation in the presence of calpain
inhibitors. Treatment of calpain inhibitors (calpain inhibi-
tor I and II, E64d) resulted in inhibition of caspase-12
cleavage induced by OGD; on the contrary, the pan-
caspase inhibitor zVAD.fmk (200 
 
m
 
M) had no effect on the
cleavage of caspase-12 (Fig. 2 D). Caspase-12 cleavage cor-
related with calpain activation as indicated by calpain-spe-
cific cleavage of nonerythroid 
 
a
 
-spectrin cleavage (Nath et
al., 1996; Fig. 2 D). OGD-induced Bcl-xL cleavage was also
inhibited by calpain inhibitors but not by zVAD (Fig. 2, C
and D). Proteasome inhibitors also had no effect on the
cleavage of caspase-12 or Bcl-xL (data not shown). Fur-
thermore, the cleavage product of Bcl-xL was detected in
caspase-12
 
2
 
/
 
2
 
 glial cells (data not shown). These data indi-
cate that OGD-induced cleavage of both caspase-12 and
Bcl-xL is mediated by calpain but not by caspases.
Although zVAD did not inhibit OGD-induced caspase-
12 and Bcl-xL cleavage, zVAD did rescue a significant
portion of cell death (Fig. 2 D). Although zVAD cannot
inhibit caspase-12 cleavage, zVAD is effective in inhibiting
caspase-12 activity (see Fig. 4 B). It is also possible that
zVAD is inhibiting caspases in addition to caspase-12,
which may be activated in parallel or downstream from
caspase-12. E64d and calpain inhibitor I also rescued a sig-
nificant portion of oxygen- and glucose-deprived glial cells
(viability: 47.2% and 45.5% by MTT assay, respectively;
Fig. 2 D), although E64d and calpain inhibitor I, like other
 
inhibitors of calpain, are toxic to cells when incubated for
an extended period of time. This could reflect the involve-
ment of calpain in normal cell homeostasis (Wang et al.,
1989; Shumway et al., 1999).
 
Caspase-12 Activation Is Induced by Fibrillar A
 
b
 
 and 
Inhibited by Calpain Inhibitor in Primary
Cortical Neurons
 
We have shown that caspase-12
 
2
 
/
 
2
 
 cortical neurons are
significantly more resistant to cell death induced by amy-
loid 
 
b
 
 peptide (1-40) than that of wild-type neurons, sug-
gesting a critical role for caspase-12 in mediating neuronal
cell death induced by fibrillar A
 
b
 
 peptide (Nakagawa et
al., 2000). To test if calpain plays a role in mediating neu-
ronal cell death induced by amyloid 
 
b
 
 peptide, we incu-
bated mouse primary cortical neurons with fibrillar A
 
b
 
 in
the presence or absence of calpain inhibitors (E64 and
MDL28170) for 48 h. Western blotting with anti–caspase-
12 antibody showed in cortical neurons after treatment of
fibrillar A
 
b
 
, caspase-12 was cleaved into a fragment identi-
cal to that of the caspase-12 fragment observed after OGD
treatment (Fig. 2 E). Since there were only 20–30% of cor-
tical neurons sensitive to fibrillar A
 
b
 
 neurotoxicity, the
majority of caspase-12 stayed intact in these cultures. The
appearance of this caspase-12 fragment was inhibited by
the addition of calpain inhibitors E64 or MDL28170 (Fig.
2 E). From these results, we concluded that calpain is also
required for fibrillar A
 
b
 
 peptide–induced caspase-12 acti-
vation.
Figure 2. The requirement of
calpain for caspase-12 activa-
tion in vivo. (A) Caspase-12
and Bcl-xL are cleaved in
glial cells under oxygen and
glucose deprivation (OGD, 9-h
treatment), but not under
hypoxia condition (oxygen
deprivation, OD). ER stress
is induced by OGD but not
by OD, as indicated by the in-
duction of BiP in OGD but
not OD-treated cells. Antitu-
bulin was used as a control
(bottom). UT; untreated. (B)
Caspase-12 is cleaved in glial
cells treated by ER stress–
inducing agents (thapsigar-
gin, 2 mM; A23187, 2 mM),
which induces ER stress as in-
dicated by BiP induction. (C
and D) The effects of pan-
caspase inhibitor (zVAD),
and calpain inhibitor (calpain
inhibitors I, II, and E64d) in
glial cells treated by OGD.
Calpain inhibitors (calpain inhibitors I and II; CI-I and -II, respectively), but not z-VAD, inhibited caspase-12 and Bcl-xL cleavages (C
and D). zVAD and calpain inhibitor partially protected glial cell death induced by OGD (D). Calpain activation correlates with
caspase-12 cleavage activity. Endogenous calpain substrate, a-spectrin, was cleaved to 145- and 150-kD fragments after OGD treatment
(D), which indicates calpain activation. (E) Fibrillar Ab peptide induced caspase-12 cleavage, and calpain inhibitors prevented caspase-
12 cleavage in primary cortical neurons. The cleavage product of caspase-12 was detected by Western blotting after 48 h of treatment
with 40 mM fibrillar Ab (25-35). Arrows indicate cleaved caspase-12 fragment. no suppl: no supplement. 
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The Involvement of m-Calpain in Calcium-dependent 
Caspase-12 Cleavage
 
Since calcium is essential for activation of calpain, we rea-
soned that calcium should be essential for caspase-12 acti-
vation as well. To examine the requirement of calcium for
caspase-12 cleavage, we used the S-100 fraction of mouse
cerebral cortex as a source of calpain to cleave in vitro–
translated caspase-12. We found that the cortical S-100
cleaved the full-length caspase-12 into three fragments
each 
 
z
 
35 kD in the presence of millimolar but not micro-
molar calcium (Fig. 3 A, lane 3). This cleavage was inhib-
ited by the addition of calcium chelators EGTA and
EDTA (Fig. 3 A, lane 4). zVAD was totally ineffective in
inhibiting caspase-12 cleavage similar to that of in vivo
cleavage of caspase-12 induced by OGD (data not shown).
This result suggests that caspase-12 is cleaved by m-cal-
pain, rather than 
 
m
 
-calpain in cortical S-100.
To confirm the involvement of m-calpain in caspase-12
cleavage, we examined in vitro cleavage of 
 
35
 
S-caspase-12
and 
 
35
 
S-Bcl-xL by purified m-calpain (Fig. 3 B, a and c).
Incubating 
 
35
 
S-caspase-12 with purified m-calpain resulted
in the formation of three fragments of caspase-12 
 
z
 
35 kD
and a 20-kD fragment, all of which were recognized by the
anti–caspase-12 p20 large subunit antibody (Fig. 3 B, b)
and very similar in their respective sizes to that observed
in vivo. Cleavage of Bcl-xL by calpain generated two frag-
ments of 25 and 13 kD; the 25-kD fragment was recog-
nized by the anti–COOH-terminal antibody of Bcl-xL.
To further confirm that the cleavage products of cas-
pase-12 by calpain in vitro are indeed the same as those
observed in vivo, we compared the sizes of endogenous
caspase-12 fragments in apoptotic glial cells induced by
OGD and those caspase-12 cleavage products generated
by incubating with S-100 or purified m-calpain side by side
on the same Western blot (Fig. 3 C). OGD induced ex-
pression of a protein (asterisk) that is slightly bigger than
the full-length caspase-12 (1). This protein is expressed at
a very low level under control conditions and may be re-
lated to caspase-12, as it is recognized by the anti–caspase-
12 antibody. Caspase-12 is expressed in two forms, the
larger one (1) in vivo (Fig. 3 C, first four lanes) exhibit
slightly faster mobility on SDS-PAGE than the larger one
(1) in vitro (Fig. 3 C, middle four lanes). The smaller form
(2) is identical in sizes in vivo and in vitro (Fig. 3 C). Three
caspase-12 fragments 
 
z
 
35 kD were detected in OGD-
treated glial cells; three caspase-12 fragments (3–5) of very
similar sizes were also detected in S-100 and calpain-
cleaved caspase-12 in vitro (Fig. 3 C). Since m-calpain and
S-100 in the presence of calcium produced three fragments
very similar to that in vivo, we concluded that calpain may
be involved in caspase-12 and bcl-xL cleavage in OGD-
treated cells.
 
Activation of Caspase-12 and Inactivation of Bcl-xL
by m-Calpain
 
To identify the cleavage sites in caspase-12 and Bcl-xL by
m-calpain, we incubated recombinant caspase-12 and Bcl-
xL with m-calpain and the cleavage products were isolated
and sequenced. The two major calpain cleavage sites in
caspase-12 were T132/A133 and K158/T159, correspond-
ing to the fragments 3 and 5 (Fig. 3 C). Both cleavage sites
are between the prodomain and the large subunit (Fig. 4
A). Bcl-xL was cleaved at one site in the loop domain,
A60/D61 (Fig. 4 A), which corresponds to the 25-kD Bcl-xL
fragment. Interestingly, this cleavage site in Bcl-xL by
calpain is very close to the reported cleavage sites in Bcl-xL
Figure 3. Cleavage of caspase-12 by calpain in vitro. (A) Cleav-
age of caspase-12 by cerebral cortex–soluble (S-100) proteins in a
calcium-dependent manner. Caspase-12 is effectively cleaved in
the presence of millimolar, but not micromolar, calcium. Activa-
tion of caspase-12 is inhibited by calcium chelators (EGTA and
EDTA). (B) Caspase-12 and Bcl-xL are cleaved by purified
m-calpain in vitro. (a) Caspase-12 is cleaved by m-calpain to gen-
erate three major fragments each z35 kD, which may autoacti-
vate themselves to generate fragments of 20 and 10 kD (arrows),
which may be the large and small subunits of caspase-12, respec-
tively. The 20-kD fragment is detected by anti–caspase-12 p20
antibody after a longer incubation with calpain (b). (c) Bcl-xL is
cleaved by m-calpain in vitro. The arrow indicates the cleaved
product that was sequenced. (C) The cleavage products of
caspase-12 in vivo are similar in sizes to those generated by in
vitro cleavage assays (S100 and purified m-calpain). The arrows
point to the procaspase-12 (arrows 1 and 2) and the cleaved prod-
ucts of caspase-12 (arrows 3–5). Cleaved products (arrows 3 and
5) were sequenced. Cleavage sites of 3 and 5 are T132/A133 and
K158/T159, respectively. The large subunit of caspase-12 (p20) is
produced in a time-dependent manner. 
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by caspase-1 (D61/S62; Clem et al., 1998) and caspase-3
(D61/S62 and D76/A77; Fujita et al., 1998). Since the
cleaved products of Bcl-xL by caspase-1 or -3 have proap-
optotic activity (Clem et al., 1998; Fujita et al., 1998), the
cleaved product of Bcl-xL by m-calpain most likely has a
similar function. These data suggest that active calpain
may convert procaspase-12 into active caspase-12 and Bcl-xL
from an antiapoptotic protein into a proapoptotic form.
To confirm that cleavage of caspase-12 at K158 indeed
activates caspase-12, we next examined whether bacteri-
ally expressed T159-N419 caspase-12 (t-caspase-12), mim-
icking calpain cleavage product of caspase-12, is active.
Although bacterially expressed t-caspase-12 is largely
present in the inclusion body and poor in solubility, the
bacterial lysate expressing t-caspase-12, but not control ly-
sate, was active in cleaving itself, and its cleavage activity
was inhibited by zVAD (Fig. 4 B). In contrast, the full-
length caspase-12 expressed in 
 
E. coli 
 
was not active (data
not shown). Procaspases are usually cleaved between the
large and the small subunits during activation (Thornberry
et al., 1992). Caspase-12 has a predicted cleavage site,
D318, which is located between the large and the small
subunits. To determine the cleavage site of caspase-12, we
generated a mutant caspase-12, D318E. Active caspase-12
cleaved the wild-type but not the D318E caspase-12 (Fig. 4
B). These data suggest that calpain-cleaved 35-kD cas-
pase-12 fragments are active, which may further cleave
themselves between the large and small subunits to gen-
erate mature caspase-12. To further compare the activity
of full-length and truncated caspase-12, we transfected the
expression vectors of full-length versus the 35-kD frag-
ment into Rat1 cells, and compared cell death after 24 h.
The truncated caspase-12 was significantly more active in
inducing cell death (33.6
 
 6 
 
2.0%) than that of full-length
caspase-12 (17.7
 
 6 
 
1.6%). From these results, we con-
cluded that cleavage of caspase-12 before T159 likely re-
sults in the activation of caspase-12.
 
Discussion
 
In this paper, we described a new mode of caspase activa-
tion. Previously, two modes of caspase activation have
been described. The long prodomain caspases may be acti-
vated through recruitment into caspase activating com-
plexes and activated through the induced proximity model
(Budihardjo et al., 1999). For example, caspase-8 is acti-
vated through direct recruitment into Fas and TNF death
signaling complex, whereas caspase-9 is activated through
recruitment into Apaf-1/cytochrome 
 
c
 
 complex. On the
other hand, the short prodomain-containing caspases such
as caspase-3 and caspase-7 are activated through direct
proteolytic cleavage by another active caspase. In this pa-
per, we described that caspase-12 may be activated by
direct proteolytic cleavage by a noncaspase protease,
namely calpain. Procaspase-12 is localized on the cytoplas-
mic side of ER, whereas inactive calpain is mainly cyto-
solic. On the other hand, calpain, upon activation by ele-
vated intracellular calcium, is known to translocate from
the cytosol to the membrane (Suzuki, 1987), where it may
cleave procaspase-12. It is possible that membrane associ-
ation of caspase-12 is a part of its inhibitory mechanism to
prevent its activation under normal conditions.
It is interesting to note that although caspase-12 is
downstream from calpain in mediating OGD-induced cell
death, zVAD-fmk is considerably more effective in inhib-
iting OGD-induced cell death than that of calpain inhibi-
tors. Calpain inhibitors consistently exhibit significant tox-
icity toward normal living cells; this is likely because of the
role of calpain in regulating cytoskeleton, signal transduc-
tion, and metabolic pathways of normal cells. On the other
hand, caspase inhibitors have exhibited significantly lower
toxicity than that of calpain towards living cells. As
caspase-12 is downstream from calpain, the effectiveness
of the caspase inhibitor also suggests that calpain activa-
tion is not sufficient to induce apoptosis. In general,
caspase inhibitors may be more suitable as therapeutical
agents than that of calpain inhibitors. Recently, however,
it was shown that caspase-8 may play a role in regulating
erythropoiesis by cleavage of GATA-1, a transcription
Figure 4. The cleavage sites in caspase-12 and Bcl-xL by m-cal-
pain. (A) Caspase-12 is cleaved in at least two sites at T132/A133
and K158/T159. Bcl-xL is cleaved at one site, A60/D61. The
cleavage site in Bcl-xL is close to that of caspase-1 or -3, (D61/
S62 by caspase-1 and -3, D76/A77 by caspase-3; Clem et al., 1998;
Fujita et al., 1998). The cleavage site of Bcl-xL is not conserved in
Bcl-2. Underlines show sequence results. (B) Truncated (T159-
N419) caspase-12 (t-caspase-12) expressed in bacteria is active in
cleaving the wild-type caspase-12 but not D318E mutant.
Caspase-12 activity is inhibited by zVAD. Arrow indicates the
cleaved product of caspase-12. (C) t-Caspase-12 induced cell
death in Rat1 cells. The percentage of cell death was determined
by morphology 24 h after transfection. Data are averages (6
SEM). 
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factor required for the terminal differentiation of eryth-
roid precursor cells (De Maria et al., 1999). It remains to
be seen whether other caspases may have a role in pro-
cesses other than apoptosis. Thus, it may be critical to de-
velop specific caspase inhibitors that can discriminate
difference between caspases. Since caspase-12
 
2
 
/
 
2
 
 mice
develop and behave normally, caspase-12 and its human
homologue may be better suited as a disease target for
treatment of chronic neurodegenerative diseases.
Active caspase-12 is not the only cytotoxic agent acti-
vated by calpain when neurons and glias are subjected
to ischemic injury in vivo or OGD in culture since cas-
pase-12
 
2
 
/
 
2
 
 cells are not resistant to OGD. In contrast,
amyloid 
 
b
 
 peptide–induced neurotoxicity appears to be
mediated predominantly through caspase-12 as caspase-
12
 
2
 
/
 
2
 
 cortical neurons are more resistant to A
 
b
 
 than that
of wild type (Nakagawa et al., 2000). The basis of such di-
chotomy may be due to the scale of calpain activation as
well as the kinetics of cleavage. Although we can detect
Bcl-xL cleavage readily in OGD-treated cells, we cannot
detect the cleavage of Bcl-xL in A
 
b
 
 peptide–treated neu-
rons (data not shown). OGD may not target the ER spe-
cifically; it has impact on mitochondria as well (Perez-Pin-
zon et al., 1999). Thus, OGD may have caused calcium
release from mitochondria as well as from the ER, which
may have resulted in higher increases in intracellular cal-
cium concentration and more generalized activation of
calpain than cells treated by A
 
b
 
 peptide. In addition, we
noticed that in vitro, caspase-12 is cleaved much more
readily than that of Bcl-xL by calpain (Fig. 3 B). Thus,
OGD may have created at least two killer proteins, active
caspase-12 and truncated Bcl-xL (Clem et al., 1998; Fujita
et al., 1998), which may explain why the loss of caspase-12
alone is not sufficient for inhibiting apoptosis induced by
OGD, whereas treatment of A
 
b
 
 peptide activates caspase-
12 specifically and inhibition of caspase-12 is sufficient to
block A
 
b peptide–induced cell death. We conclude that
caspase-12 may be an attractive therapeutic target for
Alzheimer’s disease.
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